Clincosm LogoSign in Get a demo

PRIORITY-ADHF: Intravenous Vasodilator vs. Inotropic Therapy in Patients With Heart Failure

Sponsor
Montefiore Medical Center (Other)
Overall Status
Withdrawn
CT.gov ID
NCT02767024
Collaborator
(none)
0
Enrollment
1
Location
2
Arms
1
Actual Duration (Months)
0
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Single center, prospective, randomized, non-blinded research study comparing intravenous vasodilator infusion vs. inotropic infusion in patients admitted to the hospital or in the emergency room at Montefiore Medical Center presenting with the diagnosis of acute decompensated systolic heart failure with low cardiac output but no hypotensive.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

The objective of the study is determine if the administration of diuretics with intravenous sodium nitroprusside (vasodilator therapy) in comparison to intravenous dobutamine (inotropic therapy) will lead to a reduction in the primary and secondary endpoints in patients with acute decompensated systolic heart failure with low cardiac output and no hypotensive.

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Intravenous Vasodilator vs. Inotropic Therapy in Patients With Heart Failure Reduced Ejection Fraction and Acute Decompensation With Low Cardiac Output: A Single Center, Randomized, Non-Blinded, and Parallel Study (PRIORITY-ADHF Study)
Actual Study Start Date :
May 1, 2018
Actual Primary Completion Date :
May 1, 2018
Actual Study Completion Date :
Jun 1, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: Sodium Nitroprusside

Dose titration will start at 25 μg/min and increased by 25 μg every 5 minutes to maximal dose of 400 μg/min while maintaining SBP ≥ 90 mmHg. Every 5 minutes, the Pulmonary Capillary Wedge Pressure (PCWP), SBP will be measured. If PCWP > 16 mmHg while maintaining SBP ≥ 90 mmHg, the investigator will proceed to titrate dose with the goal to achieve the target of PCWP ≤ 16 mmHg and Cardiac Index (CI) > 2.2 L·min-1·m-2, or maximal infusion dose has been reached, whichever comes earliest. Continuous intravenous furosemide infusion dose will be maintained by protocol.

Drug: Sodium nitroprusside
Sodium nitroprusside is a medication used to lower blood pressure.
Other Names:
  • Generic name for nitropress

    • Drug: Furosemide
    Furosemide is a prescription drug used to treat hypertension (high blood pressure) and edema. Learn about side effects, warnings, dosage, and more.
    Other Names:
  • Generic name for Lasix

    		•
    Active Comparator: Dobutamine

    Dose titration will start at 2.5 μg/kg/min and increased to doses of 5, 7.5 and 10 μg/kg/min (maximal dose). Every 30 minutes, the investigator will collect Pulmonary Artery (PA) blood samples for PA sat measurement to calculate Cardiac Output (CO) and CI by Fick. If CI ≤ 2.2 L·min-1·m-2, the investigator will proceed to titrate dose until CI > 2.2 L·min-1·m-2 or maximal infusion dose has been reached, whichever comes earliest. Continuous intravenous furosemide infusion dose will be maintained by protocol.

    Drug: Dobutamine
    Dobutamine is a direct-acting inotropic agent whose primary activity results from stimulation of the ß receptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects.

    Drug: Furosemide
    Furosemide is a prescription drug used to treat hypertension (high blood pressure) and edema. Learn about side effects, warnings, dosage, and more.
    Other Names:
  • Generic name for Lasix

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Arrhythmia incidence [within 72 hours after the initiation of the drug]

      defined by the presence of ventricular arrhythmia (either ventricular tachycardia or ventricular fibrillation) or supraventricular arrhythmias (either recurrent or new onset of atrial fibrillation, atrial flutter or supraventricular tachycardia) with sustained heart rate ≥ 130 beats per minute

    2. Serum troponin T release [within 72 hours after the initiation of the drug]

      defined as measured serum cardiac troponin T (cTnT) with a value > 0.10 ng/ml

    3. Hypotension incidence [within 72 hours after the initiation of the drug]

      defined as ≥ 2 consecutive blood pressure measurement with SBP < 90 mmHg

    Secondary Outcome Measures

    1. ≥2 point improvement in the 5 point Likert dyspnea scale [within 72 hours after the initiation of the drug involved in the study]

    2. ≥ 30% improvement in the 100 point global patient assessment scale [within 72 hours after the initiation of the drug involved in the study]

    3. Reduction in the Cardiac Care Unit length of stay [Up to 30 days]

      Length of stay (in hours) will be defined as the index discharge date and time minus the initiation of study drug date and time.

    4. Reduction in the hospitalization length of stay [Up to 30 days]

      Length of stay (in hours) will be defined as the index discharge date and time minus the initiation of study drug date and time.

    5. Assessment of difference in restrictive filling pattern by echocardiogram [from initiation of the of the drug involved in the study up to 72 hours.]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • History of heart failure reduced ejection fraction (HFrEF), New York Heart Association (NYHA) class IV and known left ventricular ejection fraction (LVEF ) ≤ 40% within the last 6 months by any of the following imaging techniques: echocardiogram, radio-nuclear stress test, ventriculogram or cardiac magnetic resonance imaging (CMR) performed within 6 months.

    • Hospitalized or presented to the emergency department for acute decompensated heart failure (ADHF) with the anticipated requirement if intravenous (IV) therapy (including IV diuretics). ADHF is defined as including all of the following measured at any time between the presentation (including the emergency department) and the end of the screening:

    1. Persistent dyspnea or orthopnea or edema at screening and at the time or randomization, despite standard background therapy for heart failure.

    2. Pulmonary congestion on chest radiograph.

    3. N-terminal pro b-type natriuretic peptide (NT-proBNP) ≥ 2000 pg/ml; for patients ≥ 75 years old or with current atrial fibrillation, NT-proBNP ≥ 3000 pg/ml.

    • Clinical suspicious of low cardiac output state; consider by the presence of any of the following signs or symptoms of hypoperfusion: narrow pulse pressure, cold extremities, mental obtundation, declining renal function, and/or low serum sodium.

    • Systolic blood pressure (SBP) measured ≥ 90 but < 120 mmHg at the start and the end of the screening, without use of an intravenous vasopressor therapy.

    • Hemodynamic criteria: CI ≤ 2.2 L·min-1·m-2 based on CO calculated by Fick formula and PCWP ≥ 20 mmHg measured by right heart catheterization at the time of the enrollment and confirmed by Swan-Ganz measurement upon arrival to the Cardiac Care Unit (CCU).

    • Able to be randomized within the first 24 hours from the presentation to the hospital, including the emergency department.

    Exclusion Criteria:

    • Clinical evidence of acute coronary syndrome (ACS) currently or within 30 days prior to enrollment. (Note that the diagnosis of ACS is a clinical diagnosis and that the sole presence of elevated troponin concentrations is not sufficient for a diagnosis of ACS).

    • Significant, uncorrected left ventricular outflow track obstruction, such us obstructive cardiomyopathy or severe aortic stenosis (i.e. aortic valve area < 1.0 cm2 or mean gradient > 40 mmHg on prior or current echocardiogram).

    • Severe mitral stenosis.

    • Severe aortic insufficiency or severe mitral regurgitation for which surgical or percutaneous intervention is indicated.

    • Documented, prior to or at the time of the randomization, restrictive amyloid myocardiopathy or acute myocarditis or hypertrophic obstructive, restrictive or constrictive cardiomyopathy (does not include restrictive mitral filling patterns seen on Doppler echocardiographic assessments of diastolic function).

    • Complex congenital heart disease.

    • Significant arrhythmias, which include any of the following: sustained ventricular tachycardia; atrial fibrillation or atrial flutter with sustained heart rate > 130 beats per minute.

    • Bradycardia with sustained ventricular rate < 45 beats per minute.

    • Temperature > 38.5°C (oral or equivalent) or sepsis or active infection requiring IV anti-microbial treatment.

    • History of malignancy (other than localized basal cell carcinoma of the skin), treated or untreated or any terminal illness (other than heart failure) with a current life expectancy less than a year.

    • Major surgery or major neurologic event including cerebrovascular events, within 30 days prior to enrollment.

    • Need for mechanical circulatory support (MCS), including intra-aortic balloon pump, Extracorporeal Membrane Oxygenation (ECMO) or any ventricular assist device.

    • Need for mechanical ventilatory support (endotracheal intubation or mechanical ventilation).

    • Patient with chronic heart failure and inotropic-depended.

    • Current (within 2 hours prior to screening) treatment with any IV vasoactive therapies, including vasodilators, inotropic agents and vasopressors.

    • Patients with severe renal impairment defined as pre-randomization estimated Glomerular Filtration Rate (eGFR) < 25 ml/min/1.73m2 calculated using the simplified Modification of Diet in Renal Disease (sMDRD) equalization and/or those receiving current or planned dialysis or ultrafiltration.

    • Patients with acute kidney injury defined as an increase in serum creatinine 3 times of baseline, or reduction in urine output to <0.3 mL/kg per hour for ≥12 hours, or anuria for ≥12 hours, or patients undergoing renal replacement therapy.

    • Patients with Child C cirrhosis or history of cirrhosis with evidence of portal hypertension such as varices.

    • Patients with acute liver failure and serum transaminase: aspartate transaminase (AST) and/or alanine transaminase (ALT) > 3 times above the upper limit of normal.

    • Any major solid organ transplant recipient or planned/anticipated organ transplant within 1 year.

    • Patients with hematocrit < 25%, or a history of blood transfusion within 14 days prior to screening, or active life-threatening gastrointestinal bleeding.

    • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test. .

    • History of hypersensitive to dobutamine or sodium nitroprusside.

    • Inability to follow instructions or comply with follow-up procedures.

    • Any other medical condition (s) that the investigator deems unsuitable for the study, including drug or alcohol use or psychiatric, behavioral or cognitive disorder.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Montefiore Medical Center Bronx New York United States 10461

    Sponsors and Collaborators

    • Montefiore Medical Center

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Mario Garcia, Professor, Cardiology, Montefiore Medical Center
    ClinicalTrials.gov Identifier:
    NCT02767024
    Other Study ID Numbers:
    • 2014-3586
    First Posted:
    May 10, 2016
    Last Update Posted:
    Oct 31, 2018
    Last Verified:
    Oct 1, 2018
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    Yes
    Additional relevant MeSH terms:
    Heart Failure
    Nitroprusside
    Dobutamine
    Furosemide

    Study Results

    No Results Posted as of Oct 31, 2018